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Introduction: Currently, postoperative endoleak surveillance after endovascular aortic aneurysm repair (EVAR) is
primarily done by computed tomography (CT). The purpose of this study was to determine the efficacy of contrast-
enhanced ultrasonography scans to detect endoleaks by using a novel infusion method and compare these findings with
those of CT angiography (CTA).
Methods: Twenty male patients (mean age, 70.4 years) underwent surveillance utilizing both CTA and contrast-enhanced
color Duplex imaging. One 3-mL vial of Optison (Perfluten Protein A microspheres for injection) and 57 mL normal
saline, for a total of 60 mL, were administered to each patient as a continuous infusion at 4 mL/min via a peripheral vein.
Each study was optimized with harmonic imaging, and a reduced mechanical index of 0.4 to 0.5, compression of 1 to 3,
and a focal zone below the aorta to minimize microsphere rupture. One minute was allowed from the time of infusion to
the appearance of contrast in the endograft. Flow was evaluated within the lumen of the graft and its components, as was
the presence or absence of endoleaks. Findings were compared with standard color-flowDuplex imaging and CT utilizing
CTA reconstruction protocols.
Results: All patients evaluated had modular endografts implanted for elective aneurysm repair. Contrast-enhanced duplex
scans identified nine endoleaks: one type I and eight type II. No additional endoleaks were seen on CTA. However, CTA
failed to recognize three type II endoleaks seen by contrast-enhanced ultrasound. The continuous infusion method
allowed for longer and more detailed imaging. An average of 46.8 mL of the contrast infusion solution was used per
patient.
Conclusions: Contrast enhanced Duplex ultrasonography accurately demonstrates endoleaks after EVAR and may be
considered as a primary surveillance modality. Continuous infusion permits longer imaging time. (J Vasc Surg 2006;43:
259-64.)Although the benefits of less invasive surgery and shorter
length of stay are triumphs of endovascular aneurysm repair
(EVAR), long-term surveillance is necessary to monitor for
persistent endoleaks, aneurysm growth, and potentially, rup-
ture.1 Computed tomography (CT) is currently the standard
modality used for following patients after EVAR, 2 but the
exposure to ionizing radiation and nephrotoxic contrast
agents is also of concern. Financial issues of surveillance have
also been noted, with a recent study showing 65% of post-
operative EVAR costs are due to CT scanning.3 For these
reasons, alterative surveillance methods such as duplex ultra-
sound scans have been explored.
Color duplex ultrasound has been previously reported
as having lower sensitivity and positive predictive value in
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However, the ultrasound contrast agents that have shown
marked benefit in echocardiography5-8 seem to increase
sensitivity in ultrasound surveillance after EVAR by allow-
ing improved blood flow echogenicity for better evalua-
tion.9-12 For example, a recent study of patients with ab-
dominal aortic aneurysm enlargement and no evidence of
complications were evaluated with contrast-enhanced ul-
trasound (CEUS), which identified endoleaks, challenging
the existence of what has been defined as endotension.10
Similarly, another recent study characterized several en-
doleaks found on CEUS not identified on CT as hypody-
namic, or slow leaks.9
Our study prospectively evaluated the use of a contin-
uous infusion method of ultrasound contrast in the surveil-
lance of abdominal aortic endografts in detecting endoleaks
compared with CT. Our hypothesis was that CEUS was
more sensitive than CT for endoleak detection.
METHODS
From July 2004 to May 2005, a prospective study,
approved by the Institutional Review Board of Baylor Col-
lege of Medicine, was conducted to evaluate the effective-
259
JOURNAL OF VASCULAR SURGERY
February 2006260 Henao et alness of CEUS imaging to detect endoleaks in patients who
underwent endovascular treatment for an infrarenal ab-
dominal aortic aneurysm. The standard for endoleak detec-
tion in this study was CT with contrast. We defined en-
doleak as the presence of persistent intrasac flow outside the
stent-graft. The endoleaks were characterized in relation to
the endograft, aneurysm wall, and aortic side branches, and
recorded in accordance to the White-May classification as
previously described.13,14
At our institution, patients are typically followed after a
successful endovascular aneurysm repair at 1, 6, 12, and 24
months, and annually thereafter. All men and postmeno-
pausal women seen at these follow-up intervals were asked
to participate unless there was a documented contraindica-
tion to the use of ultrasound contrast, blood products, or
albumin. Participants received an information sheet ex-
plaining the study and gave written informed consent on
the day of the scan. Exclusion criteria included patients
with a known endoleak from previous examinations, severe
iodinated contrast allergy, or evidence of renal insufficiency
marked by a serum creatinine level  1.5 mg/dL. Patients
were also excluded if there was evidence of a right-to-left
cardiac shunt or severe pulmonary or hepatic disease.
Optison (Perflutren Protein Type A Microspheres for
Injection, Amersham Health, Princeton, NJ) is a Food and
Drug Administration-approved injectable, sterile suspen-
sion of human serum albumin and octafluoropropane gas
microspheres used for contrast enhancement during echo-
cardiography. It has a half-life reported by the manufac-
turer of 1.3  0.69 minutes, and a benign toxicity profile
shown to be free of nephrotoxicity.15 Contrast was pre-
pared by using a single, 3-mL vial of Optison and 57 mL
normal saline combined in a sterile 60-mL syringe. The
solution was placed on a syringe pump set to deliver a
continuous infusion at 4 mL/min, typically delivered via a
right upper-extremity peripheral access (20-gauge angio-
catheter). An assistant was available at each study to man-
ually agitate the contrast to minimize microsphere precip-
itation during the examination.
Four experienced vascular sonographers (M. H., D. P.,
D. F., M. E.) performed all the ultrasound studies using a
3.5-MHz probe on a Phillips iU22 unit (Phillips Medical
Systems, Bothell, Wash). Ultrasonographers were blinded
to the results of previous angiographic or CT angiographic
(CTA) results. Fasting patients were scanned with grey
scale and color Duplex before the intravenous Optison
administration. Measurements of the aneurysm were re-
corded, and grey scale, color Duplex, and CEUS were used
to identify leaks.
Grey scale assessment protocols were performed, be-
ginning at the level of the renal arteries and followed to the
iliac bifurcation. Color Duplex was then performed, using a
curved array 2- to 5-MHz probe. A mechanical index of at
least 1.2 was used. Special attention was directed to the area
of maximum dilatation of the aneurysm where both limbs
of the endograft were visualized. A meticulous evaluation
for the presence of pulsatile color flow was performed at the
attachment sites proximally and distally as well as at thejunctional points of the modular grafts. Potential areas of
endoleak, such as the inferior mesenteric artery or lumbar
arteries were also inspected. The inspection was performed
in both transverse and longitudinal orientations.
The CEUS protocol included specific settings to be
used on each ultrasound machine to minimize microsphere
rupture. Harmonic imaging, a reduced mechanical index of
0.4 to 0.5, compression of 1:3, and a focal zone positioned
below the aorta allowed for the most efficient usage of
contrast. Time from the beginning of contrast infusion to
appearance in the endograft was recorded in all patients, as
well as the entire duration of the study, and the amount of
solution used. The infrarenal aorta and native aneurysm sac
was scanned after Optison injection in a longitudinal and
transverse perspective from the renal to distal iliac arteries.
Flow was evaluated within the lumen of the graft and its
components, as well as the presence or absence of en-
doleaks. All procedures were recorded on standard VHS
media for later evaluation and archiving purposes.
Computed tomography angiography was performed on
the same day (Lightspeed Ultra, GE Healthcare, Waukesha,
Wisc) before CEUS. The protocol called for the intravenous
injection of 150mLof a contrast agent at a rate of 2.5mL/s.
SmartPrep computer-automated scan technology (GE
Healthcare) was used to optimize the injection phase. The
standard scan delay for the arterial phase was 10 to 28
seconds; the delayed phase was timed to commence 70
seconds after the completion of the first scan, which took
20 seconds on average. Tomograms were reconstructed by
using a 1.5-mm algorithm from celiac to iliac arteries.
RESULTS
Twenty men (mean age, 70.4 years) participated in our
study from July 2004 to May 2005. The mean height and
weight of the group was 179 cm (range, 162 to 200 cm)
and 91 kg (range, 61 to 137kg). Patients had a mean body
mass index (BMI), calculated as kg/m2, of 28.2. Mean
aneurysm size was 5.27 cm at the time of follow-up. Aver-
age follow-up time was 8.7 months (range, 1 to 36
months). The endografts had varying modular designs and
had been electively placed.
The average volume of ultrasound contrast solution
administered to each study patient was 46.8 mL (range, 32
to 60 mL). The mean time necessary to perform the con-
trast enhanced portion of each exam was 11.8 minutes
(range, 8 to 28 minutes). BMI was then compared with
CEUS time, and a direct relationship was noted, with a
Pearson correlation coefficient of 0.47 (Fig 1). None of the
CEUS scans done after all of the CTA studies appeared to
have been affected by the use of the standard iodinated
contrast agents used in the CT scans. There were no adverse
events secondary to CEUS.
Contrast-enhanced ultrasound detected nine endoleaks
(Table). Eight of the endoleaks were classified as type II (Fig
2). Seven of the type II endoleaks were classified as lumbar
in origin, and one was identified and confirmed on CTA as
an inferior mesenteric arterial type II leak. A single type I
endoleak was noted on all modalities. This patient also
angiography of the same patient demonstrates no endoleak.
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that led to a therapeutic intervention in which an endolu-
minal extender cuff was successfully placed. Color Duplex
ultrasound scans identified four (44%) endoleaks, including
the type I endoleak. Six (67%) endoleaks were also identi-
fied with CTA. Three type II endoleaks found on CEUS
were not confirmed on CTA (Fig 3). No endoleaks were
seen on CTA that had not been found on CEUS.
DISCUSSION
Our study confirms previous observations that sug-
gested the efficacy of CEUS vs CTA. Using a continuous
infusion technique, we were able to clearly visualize eight
type II endoleaks and one type I after EVAR, whereas CTA
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Fig 1. Relationship of contrast-enhanced ultrasound (CEUS)
time with body mass index (BMI).
Table. Patient demographic data with endoleak type
identified on contrast-enhanced ultrasound, color duplex,
and computed tomography
Patient Age Leak type
Confirmed on
color US
Confirmed on
CT
1 85 II Yes Yes
2 78 None None None
3 78 I, II Yes Yes
4 71 II No No
5 78 II No Yes
6 79 II No No
7 57 None None None
8 70 None None None
9 72 None None None
10 76 None None None
11 56 II Yes Yes
12 54 None None None
13 57 None None None
14 63 None None None
15 65 II Yes No
16 82 None None None
17 80 II No Yes
18 74 II No Yes
19 62 None None None
20 70 None None None
US, Ultrasound; CT, computed tomography.identified five type II and one type I. The amount of timeFig 2. A, Cross-sectional contrast-enhanced ultrasound image of
main body of aortic endograft with a small type II endoleak
(arrow). B, A cross-sectional color duplex ultrasound scan of same
patient shows no evidence of endoleak.C,Computed tomography
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with a continuous infusion. Thus, our continuous infusion
modality may have contributed to improved detection
compared with previous reports of bolus contrast.
Reports concerning CEUS as a surveillance tool after
EVAR have all described the administration of contrast
agents in the form of a bolus.9-12,16-18 The required or
optimal dosage for administration of contrast agents after
EVAR is not known, which has been the source of reported
difficulties when using CEUS. Napoli et al10 were required
to infuse multiple boluses in two patients because they
could not show any clear endoleak with the first dose.
Bargellini et al9 found the need to increase the bolus
amount from 1.5 mL to 2.4 mL for similar reasons. After
the administration of a contrast bolus, the time available to
complete an enhanced scan was 3 to 11minutes in previous
reports.9-12,16
In our preliminary experience, the average learning
curve for using CEUS in those experienced with abdominal
vascular screening was 10 to 15 studies. The initial difficulty
was thought to be attributed to the pump setup and the
need for continuous agitation, as explained above. The
continuous infusion allowed for a longer study window,
lasting as long as 28 minutes, and allowed for a more
deliberate search for small or slow endoleaks, potentially
increasing the sensitivity and ease of the study. It also
facilitated scanning of the challenging patient with exces-
sive bowel gas or large body habitus, using even unortho-
dox views (ie, placing the patient in decubitus position)
when necessary, without the worry of missing an endoleak
because of limited contrast duration.
A weak correlation between BMI and the amount of
time it took to perform CEUS was noted. The true signif-
icance of this is unknown because of the small sample size.
Ultrasonic contrast mayminimize scanning hindrances,
such as body habitus, while optimizing those features of
vascular blood flow.19 Enhanced ultrasound with harmonic
imaging appears to diminish theses effects, as there were
Fig 3. A cross-sectional contrast-enhanced ultrasound image of
the iliac limbs of an aortic stent demonstrates a type II endoleak
(arrow) in the posterior sac.more endoleaks identified than with color duplex imaging.In our comparison of color duplex and CEUS, it was noted
that there was a tendency for more artifactual disturbances
with color flow. This was despite the use of harmonics,
compression, and adjustments in focal zone in both trans-
verse and longitudinal views. Thus, there was a clear benefit
in using contrast in that minimal-to-no change in ultrasonic
gain was required to discriminate subtle type II endoleaks
with contrast, whereas adjustments in the color modality
may have led to artifacts. More CEUS observations are
needed to clarify this preliminary data trend.
In general, the cost of an ultrasound study may range
from $350 to $1000, and a vial of the Optison contrast
agent is $140.40, according to the manufacturer. Several
patients in our series required scanning periods well past the
maximumduration reported in previous studies concerning
bolus administration of contrast. If continuous infusion
had not been used, this may have led to additional contrast
administration as well as to increased cost.
Our study is limited by its small sample size. More
patients are needed to accurately calculate the sensitivity
and specificity of the technique. It could also benefit from a
true cost analysis20 to justify the relatively expensive pur-
chase of contrast, syringe pump setup, and maintenance, as
well as the need for ancillary staff to monitor the contrast
and provide continuous syringe agitation.
CONCLUSION
The potential for malignancy secondary to radiation
exposure21 and the well-known complication of nephro-
toxicity secondary to iodinated contrast agents drives the
search for a better surveillance modality. While newer tech-
nologies such as intrasac pressure sensors22 are currently in
development, a “perfect” surveillance tool does not yet
exist. The need to characterize the dynamic flow of en-
doleaks may be useful in the decision for therapy, and
CEUS may be an excellent tool for this use. However, CT
scanning remains the gold standard in the periodic moni-
toring of aneurysm size, migration, and other physical
factors such as changes in limb position and partial limb
separation and should continue to be a part of the standard
follow-up regimen in EVAR patients.
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Dr K. Craig Kent (New York, NY). You said that there is
potential for decreased cost. Do you have any idea of what the cost
of the agent is? Can you compare this to the cost of a CT scan?
Dr Esteban A. Henao. There was a study in 2003 by Bendick,
which used a different contrast agent, demonstrating the cost effec-
tiveness of CEUS. A figure that I can give you is $140 perUS contrast
vial used in our study. And the average cost for a follow-upUS scan is
anywhere from$150 to$400, dependingon the area and thehospital.
Compare that to CT scan, which can range from $1,500 to $4,000.
Dr Ali AbuRahma (Charleston, WV). Did you follow your
patients who had CT scans by delayed imaging, which may have
shown leaks that were missed?
Second question, for patients who had duplex ultrasound
without contrast, were the leaks type I or type II, which may have
clinical significance?
When do you see this agent becoming commercially available,
since we still don’t have it here in the United States?
Dr Henao. To answer your first question, this study used a
biphasic CT scan, so there was an arterial phase and a delayed
phase.
In terms of duplex without contrast, the grey scale view was
done as part of our general evaluation, but it wasn’t used to look
for endoleaks.
Lastly, the contrast used in our study is currently FDA-DrMunierNazzal (Toledo, Ohio).What is the gold standard
here? How do you know that what you are diagnosing is not an
artifact leading to overdiagnosis of endoleak?
DrHenao.That is a good question. And I don’t know if there
are any hard data that says what is the gold standard. Right nowCT
is what we use.
Yesterday Dr Ohki gave an excellent presentation on pressure
monitoring of the sac. That may actually be the new gold standard,
depending on how that comes out.
The truth of the matter is that there is no one perfect study. I
think even if we do implement a device that evaluates pressure
measurements, we are still going towant to look at the integrity of the
device, we are still going to want to see blood flow around the
endograft. So inevitably, we are going to integrate all these different
modalities and come up with a unified way to follow these grafts.
DrKent (New York, NY). Youmay have told us the answer to
this question, but what are the next steps? How long until we have
this available in clinical practice, and what other evaluations have to
be conducted before we get to that stage?
Dr Henao. I am not sure what the answer is. I think we are
making headway. This is going to be the sixth preliminary study. I
think if we have more patients, we can present that to the FDA and
get this thing underway, because the proof is in the pudding. One
can see endoleaks and there is definitely evidence of ruptures
despite negative CT findings. So if we are missing potential disas-
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Dr Kent.One last question. Do you sense that there has to be
any special expertise in your ultrasound lab to use this technique, or
does this diminish the need for special expertise?
DrHenao. I think one of the criticisms of ultrasound in the
follow-up of EVAR is that it is operator-dependent. But with
the use of the contrast agent, there were many times that I felt
that I could probably do the scan myself, and I am by no means
a certified technologist. The clarity of blood flow makes the scan
substantially easier. However, it is still a very labor-intensive
dalities offer extensive detail about endograft integrity, aneurysmscan. I don’t know if any of you have ever seen an ultrasound of
an EVAR follow-up, but it is very hard on the technician, and I
think using the contrast helps to speed up the process signifi-
cantly.
Dr Julie Ann Freischlag (Baltimore,Md).Have you used this
technique in other arteries besides the aorta looking for endoleaks,
such as the carotid?
Dr. Henao.We have, but it is anecdotal at this stage, looking
at SFA, a string sign of the carotid, but we don’t really have a
hard-and-fast experience to comment on at this point, but it seems
to be very useful.INVITED COMMENTARYThomas L. Forbes, MD, London, Ontario, Canada
After endovascular repair of an aortic aneurysm, the infrarenal
aorta continues to demonstrate characteristic changes during
follow-up. Even in the successfully excluded aorta, there re-
mains a remodeling process reflected in changes in aortic neck,
aneurysm, and iliac artery geometry. With aneurysm sac pressur-
ization these changes are exacerbated and unpredictable, reinforc-
ing the need for long-term surveillance. Until fairly recently, many
centers have used static computed tomography (CT) images as
their surveillance modality of this dynamic remodeling. Although
quite capable of identifying significant endograft migration,
contrast-enhanced CT scans are less than perfect in identifying
the source of some endoleaks, predicting their physiologic ramifi-
cations, and in planning endoleak directed therapies.
In the present study, the Baylor group is to be commended for
further refining a contrast-enhanced ultrasound protocol for en-
dograft follow-up. They used a continuous infusion technique of
an albumin and microsphere suspension-based agent previously
used with contrast echocardiography. It proved more accurate
than CT imaging in the identification and classification of en-
doleaks and allowed for longer periods of monitoring compared
with ultrasound scans using boluses of contrast. The findings of
this 20-patient study certainly suggest further examination of this
technique is warranted. This may also prove to be a more cost-
effective method of surveillance.
Although static (CT) and dynamic (ultrasound) imaging mo-geometry, and endoleak identification and classification, they are
incapable of predicting the ramifications of these changes. This
requires a measure of aneurysm pressurization, of which aneurysm
diameter, volume, and endoleak identification are but a surro-
gate. A noninvasive method of sac pressure measurement has
recently been developed that offers the possibility of determin-
ing which aneurysms required reintervention based on physio-
logic parameters.1
As the authors suggest, the perfect surveillance tool after
endovascular repair undoubtedly involves an algorithm rather than
a single imaging modality. This includes static imaging techniques
(plain radiographs, CT, magnetic resonance) to monitor endograft
integrity and aneurysm remodeling, dynamic imaging (ultrasound)
to accurately identify and classify endoleaks, and physiologic mon-
itoring (intrasac pressure transducer) to determine the need for
reintervention. As this surveillance algorithm is elucidated further,
it is likely that follow-up regimens will become patient specific, as
all aneurysms will not require all surveillance modalities. This
continues to be an important and evolving area of endovascular
surgery that all vascular surgeons are encouraged to follow closely.
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